Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
40.78
+0.64 (1.59%)
Jul 30, 2025, 2:19 PM - Market open

Company Description

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.

The company’s lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction.

In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention.

Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals logo
CountryUnited States
Founded2016
IPO DateOct 16, 2020
IndustryBiotechnology
SectorHealthcare
Employees323
CEOBobak Azamian

Contact Details

Address:
15440 Laguna Canyon Road, Suite 160
Irvine, California 92618
United States
Phone949 409 1801
Websitetarsusrx.com

Stock Details

Ticker SymbolTARS
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$16.00
CIK Code0001819790
CUSIP Number87650L103
ISIN NumberUS87650L1035
Employer ID81-4717861
SIC Code2836

Key Executives

NamePosition
Dr. Bobak R. Azamian M.D.Co-Founder, President, Chief Executive Officer and Chairman
Jeffrey S. Farrow CPAChief Financial Officer and Chief Strategy Officer
Dr. Seshadri Neervannan Ph.D.Chief Operating Officer
Aziz Mottiwala M.B.A.Chief Commercial Officer
Dr. Elizabeth Yeu M.D.Chief Medical Officer
David NakasoneHead of Investor Relations
Dr. Bryan Wahl J.D., M.D.General Counsel and Corporate Secretary
Adrienne KempSenior Director of Corporate Communications
Matthew Rossen M.B.A.Vice President of Marketing
Scott YoumansVice President of Sales

Latest SEC Filings

DateTypeTitle
Jul 28, 2025SCHEDULE 13GFiling
Jun 18, 20258-KCurrent Report
Jun 17, 2025144Filing
Jun 16, 2025144Filing
Jun 9, 2025144Filing
May 15, 2025SCHEDULE 13G/AFiling
May 7, 2025SCHEDULE 13G/AFiling
May 1, 202510-QQuarterly Report
May 1, 20258-KCurrent Report
Apr 28, 2025ARSFiling